Prometrium What to Expect, Week-by-Week First Month

What Prometrium Is and Why It Is Prescribed

Prometrium is the FDA-approved brand of oral micronized progesterone (OMP). It is prescribed primarily to protect the uterine lining (endometrium) in women taking estrogen therapy, and secondarily for secondary amenorrhea. Unlike medroxyprogesterone acetate (MPA), micronized progesterone is bioidentical to the hormone produced by the ovary, meaning its molecular structure is identical to endogenous progesterone [1].

How It Differs from Synthetic Progestins

Synthetic progestins such as MPA carry androgenic and glucocorticoid receptor activity that micronized progesterone does not. The landmark Postmenopausal Estrogen/Progestin Interventions (PEPI) trial (N=875, published JAMA 1995) found that women randomized to conjugated equine estrogen plus OMP maintained HDL cholesterol levels that were significantly better than those in the MPA arms, with the OMP/CEE combination producing the most favorable lipid profile of all active treatment groups [2].

FDA Approval History

The FDA approved Prometrium capsules in 1998. The prescribing information specifies two indicated uses: endometrial protection in non-hysterectomized postmenopausal women receiving estrogen, and induction of secretory transformation of the endometrium in anovulatory women [3]. Off-label uses, including perimenopausal sleep support and luteal-phase supplementation in assisted reproduction, are supported by a growing body of secondary literature [4].

Pharmacokinetics: Why Timing and Food Matter So Much

Oral micronized progesterone is absorbed in the gastrointestinal tract and undergoes extensive first-pass hepatic metabolism. The FDA prescribing information notes that Cmax rises approximately 3-fold and AUC rises roughly 2.5-fold when the capsule is taken with food compared to fasting conditions [3].

The Food Effect in Practice

Taking Prometrium on an empty stomach cuts its bioavailability sharply. A 200 mg capsule taken fasted delivers systemic exposure closer to a 100 mg fed dose. Most clinicians therefore instruct patients to take the capsule at bedtime with a small snack, which also aligns timing of peak sedation with sleep onset [5].

Half-Life and Metabolite Accumulation

The terminal half-life of oral micronized progesterone ranges from 25 to 50 hours across published pharmacokinetic studies [3]. Active metabolites, including allopregnanolone, a potent positive GABA-A receptor modulator, accumulate over the first 5 to 7 days. This accumulation is the primary driver of the sedation that patients feel most intensely during week 1 [6].

Week 1: What Happens in the First Seven Days

Sedation Arrives Quickly

The most consistent first-week effect is sedation. Allopregnanolone, generated from progesterone during hepatic metabolism, binds GABA-A receptors in a manner mechanistically similar to benzodiazepines [6]. Patients often describe feeling "hit by a wave of sleepiness" within 60 to 90 minutes of the first dose. This effect peaks around days 3 to 5 as metabolite levels approach steady state.

Taking the capsule 30 minutes before planned sleep time reduces functional impairment the next morning for most women. A 2019 review in Climacteric examining sleep quality and OMP concluded that the GABA-ergic metabolite profile of micronized progesterone may genuinely improve subjective sleep quality, not merely sedate [7].

Early Bloating and Water Retention

Progesterone has a mild aldosterone-antagonist effect at high doses, but at HRT doses (100 to 200 mg), the dominant early effect is often mild water retention secondary to estrogen-progesterone interplay on renal sodium handling [8]. Patients frequently report a 1 to 2 pound scale increase during week 1. This is transient fluid, not fat. Low-sodium intake and staying well-hydrated during week 1 can reduce this effect.

Breast Tenderness

Estrogen upregulates progesterone receptors in mammary tissue. When Prometrium is added to an existing estrogen regimen, the newly activated progesterone receptors can produce breast fullness or tenderness within 48 to 72 hours [9]. This usually resolves by day 10 to 14.

Week 2: Symptoms Plateau or Begin to Settle

By day 8 to 14, allopregnanolone and other metabolites have reached pharmacokinetic steady state. For most women, the sedation that felt overwhelming in week 1 softens to something more manageable. The National Menopause Foundation notes that "side effects from progesterone therapy are most prominent in the first two weeks and tend to stabilize or improve with continued use" [10].

Mood and Anxiety Fluctuations

Some women experience mild mood changes during week 2. These are bidirectional. Women with a history of premenstrual dysphoric disorder (PMDD) may find that the allopregnanolone surge worsens anxiety or irritability, a phenomenon documented in the literature on neurosteroid sensitivity [11]. Women without that history more often report a mild calming effect. Reporting mood changes to your prescriber at the two-week mark allows early dose adjustment if needed.

Libido Changes

Progesterone can modestly suppress libido in some women by mildly reducing free testosterone through competition at sex-hormone-binding globulin. A 2021 analysis in the Journal of Clinical Endocrinology and Metabolism found that OMP had a smaller suppressive effect on free androgen index than MPA at equivalent progestogenic doses, though some reduction was still observed [12].

Digestion and GI Symptoms

Oral micronized progesterone slows GI motility via smooth muscle relaxation. Mild constipation affects roughly 10 to 15% of patients during weeks 1 and 2 based on post-marketing survey data [3]. Increasing dietary fiber and fluid intake usually resolves this without medication.

Week 3: The Adjustment Window

Week 3 is when most women experience meaningful symptom improvement. Sedation that was intrusive in week 1 is now predictable and contained to the sleeping hours. Bloating has typically reduced by 50 to 75% from its week-1 peak. Breast tenderness is usually resolving.

Assessing Whether Your Dose Is Right

The 100 mg continuous dose is standard for endometrial protection in women on transdermal estradiol at doses of 0.05 mg per day or higher. The 200 mg cyclic dose (12 days per calendar month) delivers higher per-dose progesterone exposure and is often used when a withdrawal bleed is acceptable or desired [5]. If sedation remains disabling at week 3, your clinician may consider switching to vaginal administration of 100 mg OMP, which avoids first-pass hepatic conversion to allopregnanolone and dramatically reduces sedation while maintaining endometrial protection [13].

Tracking Your Symptoms

Keeping a brief daily log during weeks 1 through 4 gives your prescriber data that transforms a follow-up call from anecdotal to evidence-based. Note: time of dose, sleep latency, morning grogginess score (1 to 10), mood, and any breakthrough bleeding. Breakthrough bleeding in weeks 3 to 4 during cyclic dosing is expected as the withdrawal effect and is not a sign of pathology.

Week 4: End-of-Cycle Evaluation

Breakthrough Bleeding on Cyclic Dosing

If you are on cyclic Prometrium (200 mg for days 1 to 12 or days 14 to 25 of the month), withdrawal bleeding typically begins 2 to 7 days after the last capsule [5]. This pattern should be predictable and light to moderate. Irregular, heavy, or mid-cycle bleeding warrants pelvic ultrasound and endometrial evaluation, as the Endocrine Society clinical practice guidelines on menopause management specify [14].

Endometrial Protection Is Now Established

After one complete cycle of cyclic progesterone or 28 days of continuous OMP, the endometrium has been exposed to sufficient progesterone signaling to counteract estrogen-driven proliferation. The PEPI investigators confirmed that the OMP arm showed endometrial hyperplasia rates statistically no different from placebo (no estrogen) after 3 years of follow-up [2]. One month is the floor; consistent multi-year adherence is what maintains that protection.

Lipid and Cardiovascular Markers

The HDL-preserving effect documented in PEPI is a long-term benefit, not a one-month result. But baseline lipid panels drawn before starting HRT and repeated at 3 months allow your clinician to verify that the expected favorable lipid trajectory is occurring. The American Heart Association notes that the type of progestogen used in combination HRT influences cardiovascular risk markers, citing the HDL differential between OMP and MPA as clinically meaningful [15].

Comparing Oral Versus Vaginal Micronized Progesterone

Route Determines Metabolite Profile

Vaginal administration of micronized progesterone (100 mg per night) delivers the drug via a uterine first-pass effect, achieving high endometrial tissue concentrations with relatively low systemic blood levels. Serum allopregnanolone concentrations after vaginal OMP are substantially lower than after oral OMP at equivalent doses [13]. Women who cannot tolerate oral sedation are often excellent candidates for vaginal use.

Endometrial Efficacy by Route

A 2018 study in Menopause (N=222) comparing oral 200 mg cyclic OMP to vaginal 100 mg cyclic OMP found comparable rates of endometrial protection, with no cases of complex hyperplasia in either arm at 12 months [16]. The vaginal route thus provides a clinically validated alternative rather than a compromise.

Practical Considerations

Vaginal capsules are not FDA-labeled for the endometrial protection indication, making this an off-label use that requires explicit informed consent and documentation. Compounded vaginal progesterone preparations also exist but fall outside FDA oversight of bioavailability standards [3].

Managing the Most Common Side Effects

Sedation Strategies

• Take the capsule exactly 30 to 45 minutes before your intended sleep time.
• Avoid alcohol within 3 hours of the dose; ethanol potentiates GABA-A activity and deepens the sedation unpredictably [6].
• If morning grogginess persists beyond week 3, ask about switching to vaginal route or splitting the dose (50 mg morning, 50 mg night), though dose-splitting has limited published evidence and requires provider approval.

Bloating Reduction

A low-sodium diet (below 2,000 mg per day) during weeks 1 and 2 reduces fluid retention. Magnesium glycinate 200 to 400 mg at bedtime may reduce bloating and support sleep without interacting with progesterone pharmacokinetics [17].

Breast Tenderness

Evening primrose oil 1,000 mg daily has weak observational support for reducing progesterone-related breast tenderness, though no large RCTs confirm this for OMP specifically [18]. Dose reduction (from 200 mg cyclic to 100 mg continuous) sometimes resolves breast tenderness by lowering peak progesterone exposure.

Mood Sensitivity in High-Risk Women

Women with a documented history of PMDD or past adverse reaction to luteal-phase progesterone should discuss neurosteroid sensitivity with their clinician before starting OMP. A 2017 paper in Psychoneuroendocrinology (N=64) found that PMDD patients showed paradoxical anxiety responses to allopregnanolone concentrations that non-PMDD controls found calming [11]. Low-dose transdermal progesterone or a synthetic progestin with low GABA-ergic metabolite conversion (such as dydrogesterone, available outside the U.S.) may be preferable in this population.

When to Contact Your Provider Immediately

Call or message your prescriber the same day for:

• Heavy vaginal bleeding (soaking more than one pad per hour for two consecutive hours) outside of expected withdrawal timing.
• New or severe headache, visual changes, or leg swelling, which may indicate thromboembolism, a rare but documented risk with any sex steroid [19].
• Chest pain or shortness of breath.
• Severe depression, suicidal ideation, or a sudden marked change in mental status.
• Jaundice or right-upper-quadrant pain (OMP is hepatically metabolized and rare cases of cholestasis have been reported) [3].

Do not stop Prometrium abruptly mid-cycle without speaking to your clinician. Abrupt discontinuation mid-cycle can trigger unscheduled withdrawal bleeding and disrupts the continuous endometrial protection in women on a continuous regimen.

What the PEPI Trial Tells Us About Long-Term Expectations

The PEPI trial (N=875, multicenter RCT, 3-year follow-up, published JAMA 1995) remains the foundational reference for choosing between OMP and synthetic progestins in HRT [2]. Key findings relevant to a woman starting Prometrium:

• Women on CEE plus OMP cyclic (200 mg for 12 days per month) showed HDL levels 1.6 mg/dL higher than the CEE-plus-MPA group at 3 years.
• Endometrial hyperplasia was rare in the OMP arm (less than 1% of participants), comparable to the placebo arm.
• The OMP arm showed the most favorable combined lipid profile (HDL, LDL, triglycerides) of all active treatment groups.

The PEPI authors wrote: "The combination of CEE and micronized progesterone had the most favorable effect on HDL-C and no excess risk of endometrial hyperplasia." This remains the most cited direct comparison of OMP versus MPA in menopausal HRT [2].

Prometrium in the Context of Current Guidelines

The Menopause Society (formerly NAMS) 2022 position statement endorses micronized progesterone as a preferred progestogen for HRT, citing its superior lipid and cardiovascular marker profile compared to MPA and its lower association with breast cancer risk in observational data [20]. The Endocrine Society similarly notes that bioidentical progesterone is an acceptable option for endometrial protection in its 2015 clinical practice guideline on menopause management [14].

The British Menopause Society goes further, stating in its 2020 guidance that micronized progesterone (branded as Utrogestan in the UK) is associated with a lower risk of venous thromboembolism compared to oral synthetic progestins, though absolute risks remain low with either agent [21].